Nxera Pharma (SOLTF) News Today $8.05 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) AgonistNovember 13, 2024 | markets.businessinsider.comNxera Pharma and Antiverse to design antibodies targeting GPCRsNovember 6, 2024 | msn.comNxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AINovember 5, 2024 | globenewswire.comNxera Pharma Reports Increased Revenue but Continues to Face LossesNovember 4, 2024 | markets.businessinsider.comNxera Pharma Reports Robust Revenue Growth Amid Strategic ExpansionNovember 2, 2024 | markets.businessinsider.comNxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024November 1, 2024 | globenewswire.comJ.P. Morgan Reaffirms Their Buy Rating on Sosei Group (SOLTF)October 26, 2024 | markets.businessinsider.comNxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024October 23, 2024 | globenewswire.comNxera Pharma to Host R&D Day 2024October 18, 2024 | globenewswire.comNxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma JapanOctober 1, 2024 | globenewswire.comNxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in JapanOctober 1, 2024 | globenewswire.comNxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of InsomniaSeptember 24, 2024 | globenewswire.comNxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568September 2, 2024 | markets.businessinsider.comElite Pharmaceuticals, Inc. (ELTP) Q1 2025 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comNxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024August 9, 2024 | globenewswire.comNxera Pharma Webinar Presentation for Q2 FY2024 Financial ResultsJuly 9, 2024 | globenewswire.comNxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D MilestoneJune 26, 2024 | globenewswire.comNxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023June 18, 2024 | globenewswire.comNxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic AreaMay 30, 2024 | globenewswire.comNxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 9, 2024 | finance.yahoo.comNxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024May 9, 2024 | globenewswire.comFDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency DisorderApril 29, 2024 | msn.comNxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU PlanApril 17, 2024 | finance.yahoo.comNxera and Handok partner for PIVLAZ supply in South KoreaApril 15, 2024 | msn.comNxera Pharma Announces Supply And Distribution Deal With Handok For PIVLAZ In South KoreaApril 15, 2024 | nasdaq.comNxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South KoreaApril 15, 2024 | finance.yahoo.comNxera Pharma joins the World Orphan Drug AllianceApril 8, 2024 | finance.yahoo.comNxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APACApril 3, 2024 | finance.yahoo.comNxera Pharma is the New Name for Sosei GroupMarch 31, 2024 | globenewswire.comSosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera PharmaMarch 27, 2024 | finance.yahoo.comSosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel DiseaseMarch 20, 2024 | finance.yahoo.comBoehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophreniaMarch 11, 2024 | finance.yahoo.comSosei Heptares to receive US$2.5 million milestone payment from Formosa PharmaceuticalsMarch 6, 2024 | finance.yahoo.comSosei Group Corporation (SOLTF)March 1, 2024 | finance.yahoo.comSosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head OfficeFebruary 15, 2024 | globenewswire.comSosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023February 13, 2024 | finance.yahoo.comSosei Heptares Webinar Presentation for FY2023 Financial ResultsJanuary 22, 2024 | finance.yahoo.comSosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating OfficerJanuary 5, 2024 | finance.yahoo.comSosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare ConferenceDecember 21, 2023 | finance.yahoo.comSosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South KoreaDecember 7, 2023 | finance.yahoo.comSosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical StudiesDecember 6, 2023 | finance.yahoo.comSosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel DiseaseNovember 24, 2023 | finance.yahoo.comSosei Group Corp 4565November 14, 2023 | morningstar.comSosei Group reports Q3 resultsNovember 10, 2023 | msn.comSosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023November 10, 2023 | finance.yahoo.comSosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal DiseasesNovember 10, 2023 | finance.yahoo.comSosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2023November 7, 2023 | finance.yahoo.comSosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 TrialNovember 5, 2023 | finance.yahoo.comSosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of InsomniaOctober 31, 2023 | finance.yahoo.comSosei Heptares Will Receive US$3.75 Million Payment in Multi-Target PartnershipOctober 31, 2023 | finance.yahoo.com Get Nxera Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SOLTF and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! SOLTF Media Mentions By Week SOLTF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SOLTF News Sentiment▼0.640.47▲Average Medical News Sentiment SOLTF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SOLTF Articles This Week▼00▲SOLTF Articles Average Week Get Nxera Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SOLTF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News AXIM Biotechnologies News BerGenBio ASA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SOLTF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nxera Pharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nxera Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
